Détail de l'auteur
Documents disponibles écrits par cet auteur (308)
Rapport
OEDT = EMCDDA ; D. HEDRICH ; K. PALCZAK ; K. KEPA ; N. SINGLETON | Lisbon : OEDT / EMCDDA | Manuals | 2021This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]Rapport
J. MARSDEN ; A. C. OGBORNE ; M. FARRELL ; RISH B. ; OMS / WHO ; UNDCP ; OEDT = EMCDDA | Genève : OMS / WHO | 2000These guidelines describe methods for the evaluation of treatment services and systems for substance use disorders. The guides are intended to be a companion resource to the WHO/UNDCP/EMCDDA workbook series on the evaluation of costs and effects[...]Rapport
FRANÇAIS : Le présent projet avait pour objectif de rassembler l'information relative aux programmes de formation post-graduée sur les drogues existant en Europe, et d'étudier l'utilité et la faisabilité d'une mise en réseau de ces programmes [...]Rapport
Commission des communautés européennes = Commission of the European communities ; OEDT = EMCDDA | 1993FRANÇAIS : Ce document constitue un recueil de la majorité des textes officiels de la communauté européenne depuis environ vingt ans. Il s'agit d'une des premières publications de l'Observatoire Européen des Drogues dont les objectifs et l'org[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV ; A. ALMEIDA ; R. CHRISTIE ; P. DUQUE ; A. GALLEGOS ; R. JORGE ; J. DE MORAIS | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2020This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on [...]Rapport
This paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member States’ commitment to the issue. It also examines to what extent legal activity may be attributed to the EU action plan on drugs. Am[...]Rapport
This thematic paper looks at the extent to which legislative attention was paid in the period 2000-2004 to actions considered by Member States to be of high priority at the outset of the strategy and action plan. Over 250 legal texts were analys[...]Rapport
The open sale of cannabis products in Europe has raised concerns among policymakers, both with regard to the legal status of these products and their potential for harm. The products are marketed for their low THC (tetrahydrocannabinol) content,[...]Rapport
OEDT = EMCDDA ; M. P. SCHAUB ; J. Y. C. LEE ; A. PIRONA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals s[...]Rapport
This paper aims to provide an overview on the development of the evaluation process of the EU Strategy and Action Plan on Drugs. A large part of the initiatives and action impacting on the drug phenomenon are under the direct responsibility of [...]Chapitre
OEDT = EMCDDA | 2012FRANÇAIS : L'usage de drogue est associé directement et indirectement à une grande diversité de conséquences négatives sur la santé et la vie sociale. Ces problèmes concernent dans une mesure disproportionnée les usagers d'opiacés de longue dur[...]Rapport
This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en-PINACA. The report is intended for policymakers and decision-makers in the inst[...]Rapport
OEDT = EMCDDA ; A. M. DINES ; D. M. WOOD ; P. I. DARGAN | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2014This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over t[...]Rapport
ENGLISH: What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other q[...]Congrès
Reitox Academy for Baltic countries: Monitoring trends in and responses to drug-related infectious diseases among people who inject drugs (21-22 November 2013; Tallinn) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This meeting, a regional Reitox Academy held in Tallinn (21-22 November 2013) contributed to maximising synergies at national level between institutions and experts in the fields of drug monitoring and infectious disease surveillance in four cou[...]Congrès
3rd Meeting on detecting and responding to outbreaks of HIV among people who inject drugs (18 November 2013; Bucharest) ; Roundtable on the HIV situation among people who inject drugs in Romania (19 November 2013; Bucharest) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This expert meeting held in Bucharest (18-19 November 2013) provided an important opportunity for sharing knowledge and best practice among experts from six countries in the south and south-east of the European region (Cyprus, Greece, Hungary, M[...]Rapport
This publication is the first in a series dedicated to prevalent illicit synthetic stimulant drugs, also known as amphetamine-type stimulants (ATS). The ATS category is made up of two groups of substances. This study focuses on the supply and us[...]Rapport
This report examines the relatively recent emergence of methamphetamine production in Afghanistan and identifies actions that may be taken in Europe to mitigate the risks. The publication stresses the importance of increasing awareness on the is[...]Rapport
This report provides a comprehensive overview of the methamphetamine market in the European Union. It assesses the current threat situation regarding current trends in production, trafficking and distribution.Rapport
OEDT = EMCDDA ; D. M. WOOD ; P. I. DARGAN | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2014This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), that was conducted by the Scientific Committee of the EMCDDA. Concerns over t[...]Rapport
This publication presents the data and findings of the risk assessment on 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. O[...]Document multimédia
This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social respon[...]Rapport
A better understanding of the complex science of 'addiction' can improve responses to drug problems. This report contains a critical review of existing addiction theories and explores how these can be organised into an overarching structure to i[...]Rapport
This report provides an overview of the changes in cannabis policies in the Americas and the evidence emerging from evaluations of their impact. Highlighting the challenges in monitoring and evaluating regulatory changes in the drugs field, it w[...]Rapport
FRANÇAIS : Ce rapport explore la manière dont, à travers des enquêtes sur des populations ciblées, sont recueillies des données sur l'usage de drogues dans l'espace récréatif public (pubs, bars, clubs, scènes musicales) et privé en Europe. Il r[...]Rapport
This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID). The barometer is being developed by the EMCDDA together w[...]Rapport
Drug-related mortality is a complex phenomenon, which accounts for a considerable percentage of deaths among young people in many European countries. The EMCDDA, in collaboration with national experts, has defined an epidemiological indicator wi[...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; M. BUSTER ; A. ESPELT ; J. MATIAS ; J. VICENTE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2015This paper examines the overall number of lives lost due to drug use. All-cause mortality among problem drug users is investigated by means of cohort studies, which link data from death registries to drug treatment records. Building on earlier w[...]Rapport
This Selected issue focuses on mortality among drug users due to all causes, of which drug-induced deaths (overdoses) is only a component, albeit the one most well-documented. The publication begins with an introduction to mortality cohort studi[...]Rapport
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publicatio[...]Rapport
OEDT = EMCDDA ; F. FAGGIANO ; R. MOLINAR | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014During adolescence, some young people may experiment with both licit and illicit substances (alcohol, tobacco, cannabis and other drugs). This can have an impact on their behaviour, their relationships with others and how they function in societ[...]Rapport
FRANÇAIS : Cette « Question particulière » de l'OEDT concernant la recherche nationale en matière de drogue en Europe décrit brièvement le cadre dans lequel la recherche en matière de drogue est menée dans les pays européens. Elle examine plus[...]Rapport
This workbook is part of a series intended to educate programme planners, managers, staff and other decision-makers about the evaluation of services and systems for the treatment of psychoactive substance use disorders. This workbook describes s[...]Rapport
OEDT = EMCDDA ; V. AUWÄRTER ; J. DE MORAIS ; A. GALLEGOS ; M. EVANS-BROWN ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2021This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in E[...]Rapport
This paper gives an overview of some recent developments in the tools most commonly used to manage national drug policies: strategies, coordination mechanisms and evaluations. It is based on an analysis of reports on national drug policies compi[...]Rapport
This update from the EU Early Warning System overviews the NPS situation in Europe in 2020-2021 and highlights emerging threats to support early warning, preparedness planning and response measures. In addition, it reflects on the changes and th[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; R. JORGE ; J. DE MORAIS ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2020In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. The report covers the p[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; W. FRANCIS ; R. CHRISTIE ; A. CUNNINGHAM ; J. SEKULA ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2015FRANÇAIS : De nouvelles substances psychoactives (NSP ou «nouvelles drogues») ont été détectées dans l'Union européenne l'année dernière au rythme de deux par semaine environ. Au total, 101 nouvelles substances ont été signalées au système d'al[...]Rapport
This short report provides an overview of how European countries are developing innovative legal responses to the challenges presented to public health and drug policy by the rapidly evolving market for new psychoactive substances.Rapport
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing law[...]Rapport
OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2018This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]Chapitre
OEDT = EMCDDA | 2012FRANÇAIS : En Europe et dans le monde, les nouvelles drogues et les nouveaux modes de consommation attirent de plus en plus l'attention du monde politique, des médias et du public. Cette situation s'explique, en partie, par les évolutions des t[...]Document multimédia
FRANÇAIS : Ce mini-guide s'inscrit dans le cadre plus vaste du document intitulé "Réponses sanitaires et sociales apportées aux problèmes de drogue : un guide européen". Il fournit une vue d'ensemble des aspects les plus importants à prendre en[...]Rapport
FRANÇAIS : Ce court rapport (« snapshot ») porte sur la vente en ligne de nouvelles substances psychoactives. Alors que 170 magasins en ligne vendant de nouvelles substances psychoactives (« legal high ») et livrant à au moins un pays membre de[...]Document multimédia
This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social respon[...]Rapport
This report presents an analysis of the drug markets in the European Neighbourhood Policy-East region covering Armenia, Azerbaijan, Belarus, Georgia, Moldova and Ukraine. Focused on providing insights into drug production, trafficking, sale, use[...]Rapport
This report presents an analysis of the drug markets in the European Neighbourhood Policy-South region covering Algeria, Egypt, Israel, Jordan, Lebanon, Libya, Morocco, Palestine, Syria and Tunisia. Focused on providing insights into drug produc[...]Document multimédia
The use of mass media campaigns as a drug prevention intervention is relatively common, but it is not without controversy. Both policymakers and practitioners have debated the effectiveness of such campaigns in reducing drug use among young peop[...]Document multimédia
The European market for hashish is currently one of the world's largest and most profitable. About 647 tons of cannabis herb and 641 tons of hashish were consumed in the European Union in 2013 and the retail market has an overall value estimated[...]Document multimédia
Cannabis is Europe's most commonly used illicit drug, with approximately 20 million adults, or around 6% of the population aged 15-64 years, having used the drug in the last year. An indication of the public health impact of the drug can be seen[...]Document multimédia
Cocaine is Europe's most commonly used illicit stimulant drug, with about 3.6 million adults (aged 15-64) estimated to have used it in the last year. It is the second most seized drug in Europe, after cannabis. Cocaine is trafficked to Europe fr[...]Document multimédia
Comorbidity of substance use and mental health disorders refers to the co-occurrence of a substance use disorder and another mental health disorder in the same individual. In Europe, the presence of psychiatric disorders associated with substanc[...]Document multimédia
FRANÇAIS : Les salles de consommation de drogues à moindre risque dans lesquelles des drogues illicites peuvent être consommées sous la supervision de personnel qualifié, existent en Europe depuis une trentaine d'années. Ces infrastructures ont[...]Document multimédia
Every year, several thousands of cocaine-related emergencies are reported in Europe, along with hundreds of cocaine-related deaths. The types of cocaine-related problems reported are wide-ranging and the relatively high prevalence of cocaine use[...]Document multimédia
Methamphetamine is an established stimulant drug in many parts of the world (e.g. South-east Asia, US), where it has long caused major public health problems. While methamphetamine use in Europe has historically been confined to the Czech Republ[...]Document multimédia
The emergence of new psychoactive substances (NPS) over the last decade has posed a major challenge to drug policy. While the limited available data indicates that prevalence levels of NPS use are relatively low in the general European populatio[...]Document multimédia
Hepatitis C is the most common infectious disease in injecting drug users, among whom it is usually transmitted through the sharing of injecting equipment such as needles and syringes. Most of those who become infected go on to develop chronic H[...]Document multimédia
Over 50 synthetic cathinone derivatives were detected via the EU Early Warning System (EU-EWS) between 2005 and 2013. This 'Perspective on drugs' explores new worrying localised and national outbreaks of injecting these substances and recommends[...]Document multimédia
The Internet is now recognised as a plausible vehicle for delivering drug and alcohol education, prevention and treatment programmes in a range of settings. This 'Perspective on drugs' charts developments in Internet-based drug treatment (IBDT),[...]Document multimédia
Recent years have witnessed a proliferation of new psychoactive substances becoming available in Europe. This can be illustrated through the rise in notifications of new substances to the EU early warning system, from just 14 per year in 2005 to[...]Document multimédia
FRANÇAIS : Trois conventions des Nations unies constituent le cadre juridique international pour le contrôle des drogues illicites. Elles recommandent aux pays de restreindre l'offre de drogues et de limiter leur utilisation à des fins médicale[...]Document multimédia
Europe has long been one of the world's largest consumer markets for cannabis, particularly resin imported mainly from Morocco. In this analysis, we report how Europe's consumer market for cannabis is increasingly dominated by herbal products, w[...]Document multimédia
FRANÇAIS : L'héroïne est traditionnellement importée en Europe sous deux formes, la plus courante étant l'héroïne brune (forme chimique base), produite essentiellement en Afghanistan et dans d'autres pays de l'Asie du Sud-Est. L'héroïne blanche[...]Document multimédia
More than 9 000 lives were reported to be lost to drug overdoses in Europe (28 EU Member States, Turkey and Norway) in 2016, the latest reporting year, and this is an underestimate. Reducing drug-related deaths therefore remains a major challeng[...]Document multimédia
The use of substitution drugs for the treatment of opioid dependence represents a key evidence-based response to heroin problems in Europe. However, the diversion of these medicines from their intended use in drug treatment to non-medical use an[...]Document multimédia
FRANÇAIS : Les cannabinoïdes de synthèse représentent le plus grand groupe de substances actuellement suivies en Europe par l'EMCDDA grâce au système d'alerte rapide de l'UE. Cette analyse présente les connaissances actuelles sur ces substances[...]Document multimédia
Synthetic drugs have been produced illicitly in Europe for over 40 years and, by global standards, Europe remains a significant producer today. Described in this analysis are current trends in illicit synthetic drug production in Europe and some[...]Document multimédia
Benzodiazepines are a widely prescribed group of medicines with a range of clinical uses, including the treatment of anxiety and insomnia and the management of alcohol withdrawal. For a number of reasons this group of medicines are often misused[...]Document multimédia
On the basis of an external evaluation of the EU drugs strategy 2005-12, on 7 December 2012 the Justice and Home Affairs Council of the European Union endorsed a new EU drugs strategy (2013-20). The strategy was designed to be implemented by two[...]Document multimédia
Psychosocial interventions are structured psychological or social interventions used to address substance-related problems. They can be used at different stages of drug treatment to identify the problem, treat it and assist with social reintegra[...]Document multimédia
The EMCDDA has carried out a meta-analysis of six reviews examining the effectiveness of medications used in treating cocaine problems. The original reviews, undertaken by the Cochrane Drugs and Alcohol Group, involved 92 studies (85 in the US) [...]Document multimédia
Perspectives on drugs (PODs) Trends in heroin use in Europe - what do treatment demand data tell us?
The current number of problem opioid users in Europe can be estimated at about 1.4 million, or 0.41% of the adult population, with heroin being by far the most widely used opioid. Heroin use has developed along different timelines; several weste[...]Document multimédia
The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this 'Perspective on drugs'. The project in question analysed wastewater in 82 European cities and towns to explore the drug-taki[...]Rapport
ENGLISH : How problem drug use develops over time in Europe is only known through indirect indicators - such as treatment presentations, drug seizures or drug related deaths - and from a limited number of cities. Estimates of the incidence of [...]Rapport
C. COSTA STORTI, Coordonnateur ; OEDT = EMCDDA | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2011The European Union Drug Strategy for the period 2009-12 sets the goal to yield concrete and identifiable improvements concerning the knowledge of drugs trafficking. In addition, the EU Drugs Action Plan for 2009-12 defines among others the objec[...]Chapitre
OEDT = EMCDDA | 2012FRANÇAIS : Ce chapitre se penche sur les évolutions politiques apparues récemment dans l'Union européenne et examine la mesure dans laquelle les États membres ont intégré leurs stratégies de lutte contre les drogues licites et illicites et étab[...]Rapport
FRANÇAIS : Cette «Question spécifique» concerne l'usage concomitant ou consécutif de différentes substances licites et illicites (polyconsommation) chez les adolescents, les jeunes adultes et les usagers problématiques de drogues. Afin de décr[...]Chapitre
FRANÇAIS : La définition générale de la «polytoxicomanie» utilisée par beaucoup d'États membres est la consommation abusive - de façon simultanée ou séquentielle - de plusieurs drogues ou types de drogues par un individu (selon la définition de[...]Rapport
OEDT = EMCDDA ; S. MINOZZI ; L. AMATO ; M. DAVOLI ; M. FERRI ; A. BO ; R. SIMON | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014Illicit opioid consumption during pregnancy brings with it the risk of an increase in obstetric complications for the mother and a range of potential dangers for the child, both before and after birth. The primary goal when treating opioid depen[...]Rapport
This Selected issue gives a broad overview on the extent of, and available responses to, the problems of pregnant drug users and families that are affected by drug use. In the first part of the report, a description of the available data on the [...]Rapport
OEDT = EMCDDA ; D. THANKI ; J. MATIAS ; P. GRIFFITHS ; A. NOOR ; D. OLSZEWSKI ; R. SIMON ; J. VICENTE | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2012This report brings together, for the first time in Europe, an integrated overview of the prevalence of intensive cannabis use, defined as daily or almost daily cannabis use (use on 20 or more days in the month preceding survey). Self-reported da[...]Rapport
Drug overdose is one of the major causes of death among young people in Europe. This paper considers how naloxone - an effective antidote that can reverse opioid intoxication - combined with training in first aid for coping with an overdose for [...]Rapport
OEDT = EMCDDA ; J. STRANG ; R. McDONALD ; D. HEDRICH ; R. SIMON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016This publication examines the case for distributing naloxone, an emergency medication, to people who inject opioids such as heroin and to others who might witness an opioid overdose. Through its capacity to reverse opioid overdose, naloxone can [...]Rapport
European Centre for Disease Prevention and Control ; OEDT = EMCDDA | Lisbon : OEDT / EMCDDA | Joint reports | 2023This joint guidance report explores good public health practices that can support effective policies to reduce infections. Common blood-borne viruses in this group include HIV, hepatitis B and hepatitis C. These are mainly spread through the sha[...]Rapport
This publication is an update of Prevention of substance abuse, published in 2007. Like the previous analysis, it is a translation of a German study that presents a state-of-the-art review of prevention science. Although originally targeted at t[...]Rapport
OEDT = EMCDDA ; L. MONTANARI ; L. ROYUELA ; I. HASSELBERG ; L. VANDAM | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2021FRANÇAIS : Ce rapport examine en profondeur un large éventail de problèmes en milieu carcéral, notamment la consommation de drogues et ses méfaits, les réponses sanitaires et sociales et l'approvisionnement en drogues. Il note que, si, dans pl[...]Document multimédia
ENGLISH: People in prison are more likely to use drugs than those in the general population. In order to respond to their health and social needs, it is vital to have a sound understanding of the interventions available in prisons and which wor[...]Rapport
FRANÇAIS : On estime qu'environ 635 000 personnes sont détenues dans des institutions carcérales dans l'Union européenne. Des travaux de recherche montrent que les problèmes de drogue sont bien plus répandus au sein de cette population qu'au s[...]Chapitre
FRANÇAIS : En dépit de la longue histoire de sa consommation et de sa popularité actuelle, notre compréhension de l'impact du cannabis sur la santé publique reste limitée. Récemment, les signes d'une relation éventuelle entre la consommation du[...]Rapport
This report describes the context of substance use and the utilisation of healthcare services among applicants for international protection in EU+ countries. This joint EMCDDA-EUAA study aims to identify the key issues and define recommendations[...]Rapport
A crucial element in evaluating drug policy, and an important indicator of political commitment to the drugs issue, is the estimation of governments’ expenditure to counter the problem. This thematic paper offers an overview of the state of rese[...]Rapport
OEDT = EMCDDA ; European Centre for Disease Prevention and Control | Lisbon : OEDT / EMCDDA | Joint publications | 2018What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA, present the evidence on active case finding as a key measure to diagnose commun[...]Rapport
OEDT = EMCDDA ; European Centre for Disease Prevention and Control | Lisbon : OEDT / EMCDDA | Joint publications | 2018This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on three high-burden blood-[...]Rapport
This is the final version of the questionnaire on drug use among prisoners at European level. The questionnaire is the results of several years of work in the field of drugs and prison, which has included the agreement on a methodological framew[...]Rapport
FRANÇAIS : Le document résume les points essentiels du Rapport Annuel de l'OEDT sur l'état du phénomène de la drogue dans l'Union Européenne. 1.Les nouvelles tendances de consommation et les problèmes liés à la drogue (vue d'ensemble par produ[...]Rapport
FRANÇAIS : Le cannabis reste la substance illicite la plus communément consommée dans tous les pays de l'UE. La consommation d'héroïne concerne moins d'un adulte sur 100 mais est la cause de la plupart des problèmes liés à la drogue dont la cr[...]Rapport
FRANÇAIS : Ce rapport est découpé en deux principales parties : la situation de la drogue regroupant la consommation, la demande de traitement, les infections et décès, la criminalité et le marché de la drogue. Une deuxième partie regroupe les[...]Rapport
FRANÇAIS : Le cannabis demeure la drogue illégale la plus couramment consommée dans l'UE. 15% des étudiants âgés de 15 ans qui ont expérimenté le cannabis au cours de l'année écoulée sont de "gros consommateurs" (à partir de 40 consommations a[...]Rapport
FRANÇAIS : Ce rapport donne un aperçu du phénomène de la drogue dans 29 pays de l'Europe avec un taux de prévalence qui s'élève à deux millions pour les usagers problématiques. Si le cannabis reste encore la drogue la plus populaire, on assi[...]Rapport
FRANÇAIS : Les données statistiques reprises dans ce document se rapportent à l'année 2004 (ou à la dernière année disponible). Le cannabis reste la drogue illicite d'origine végétale la plus produite et la plus sujette au trafic dans le monde[...]